Metrics to compare | XFOR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXFORPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.7x | 12.3x | −0.5x | |
PEG Ratio | −0.07 | −0.04 | 0.00 | |
Price/Book | 2.0x | 5.0x | 2.6x | |
Price / LTM Sales | 10.5x | 5.5x | 3.2x | |
Upside (Analyst Target) | 190.5% | 76.4% | 48.8% | |
Fair Value Upside | Unlock | 7.3% | 6.9% | Unlock |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.